Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.59 |
| ▸ | CTSS | P25774 | 8/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13896971 | 1.00 | CTSK (0.59) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8245652 | 1.00 | CTSK (0.59) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5532831 | 0.87 | CTSK (0.58) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18925259 | 0.87 | CTSK (0.58) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18892598 | 0.87 | CTSK (0.58) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL23016033 | 0.85 | CTSK (0.61) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12965804 | 0.85 | CTSK (0.61) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15435539 | 0.85 | CTSK (0.59) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1688825 | 0.85 | CTSK (0.59) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL318796 | 0.85 | CTSK (0.64) | CTSKCTSSCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112368263-B | Dipeptidyl ketoamide m-methoxyphenyl derivative and application thereof | 兰德施泰纳根梅德公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2018138500-A1 | PROCESS FOR PREPARING PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018065611-A1 | 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE | Oxford Drug Design Limited (GB) | 2018-04-12 | — | — | WO | disclosed |
| US-9796705-B2 | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-9139569-B2 | Fused tricyclic aryl compounds useful for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140256694-A1 | STEROID ANTIBIOTIC CONJUGATES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256658-A1 | Antibiotic Conjugates | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256666-A1 | ANTIBIOTIC CONJUGATES WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256696-A1 | Steroid conjugates | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256660-A1 | ANTIBIOTIC CONJUGATES LINKED WITH STEROID DRUGS | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256651-A1 | Cyclosporine A steroid conjugates | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | SCHERING CORPORATION | 2013-06-20 | — | — | US | disclosed |
| US-20120251491-A1 | FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256666-A1 | ANTIBIOTIC CONJUGATES WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | MMP17, NAALAD2, DNPEP | CTSK 141/4885CTSS 127/4885CYP1A2 135/4885 |
| US-20140256694-A1 | STEROID ANTIBIOTIC CONJUGATES | CYP17A1, CYP21A2, HSD17B1 | CTSK 289/4885CTSS 222/4885CYP1A2 79/4885 |
| US-20140256660-A1 | ANTIBIOTIC CONJUGATES LINKED WITH STEROID DRUGS | CYP21A2, CYP17A1, CYP46A1 | CTSK 290/4885CTSS 280/4885CYP1A2 198/4885 |
| US-20140256658-A1 | Antibiotic Conjugates | NAALAD2, DNPEP, ENGASE | CTSK 51/4885CTSS 46/4885CYP1A2 331/4885 |
| US-20140256696-A1 | Steroid conjugates | CYP21A2, CYP17A1, HSD17B2 | CTSK 314/4885CTSS 237/4885CYP1A2 56/4885 |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | HAVCR2, ELOC, ZC3HAV1 | CTSK 3145/4885CTSS 1340/4885CYP1A2 364/4885 |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ZC3HAV1, HAVCR2, ZC3HAV1L | CTSK 672/4885CTSS 381/4885CYP1A2 1816/4885 |
| US-20120251491-A1 | FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, ZC3HAV1, AADAC | CTSK 853/4885CTSS 408/4885CYP1A2 259/4885 |
| US-20140256651-A1 | Cyclosporine A steroid conjugates | CYP21A2, CHP1, CYP51A1 | CTSK 66/4885CTSS 29/4885CYP1A2 122/4885 |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | CTSK 1641/4885CTSS 276/4885CYP1A2 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.